Skip to content
CancerIndex

Publication

Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.

Authors not recorded

Blood2011PMID 21613260stubpubmedProvenance
Source
PubMed
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Run
ING-CIVIC-20260908-000001
Published

Abstract

Abstract (excerpt)

Only the opening of the abstract is shown; abstract text may carry publisher copyright.

Data not yet available

No abstract stored. Read on PubMed

Linked entities

Linked entities (7)

How each link was made (MeSH, dictionary, registry reference, curation…) and whether it has been validated. Candidate links are not counted in entity statistics.

Validated 7

Curated evidence

Evidence citing this paper (2)

civicProvenance
Source
CIViC — Clinical Interpretation of Variants in Cancer
Dataset
CIViC evidence items
Version
civic-2026-09-08
Retrieved
Sep 8, 2026
Layer
normalized (units and labels harmonized; values unchanged)
Evidence
expert curation
License
CC0 1.0
PMID
21613260
Run
ING-CIVIC-20260908-000001
Open at source CuratedShowing 1–2 of 2 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.
TherapyCancerTypeLevelDirection · significanceRating (1–5)StatusEvidenceSource
PML A216V + RARA FusionRARAPML1
TretinoinAcute Promyelocytic LeukemiaPredictiveCSupports Resistance4accepted
EID1093

The mutation A216V in the B2 domain of PML in the PML-RARa fusion was seen in a patient with ATRA-resistant acute promyelocytic leukemia.

PMID 21613260 · Goto et al., 2011 · Open in CIViC

civic
PML L218P + RARA FusionRARAPML1
TretinoinAcute Promyelocytic LeukemiaPredictiveCSupports Resistance3accepted
EID1094

The PML L218P mutation in the PML-RARa fusion was observed in a patient with previously ATRA-treated, relapsed acute promyelocytic leukemia refractory to arsenic trioxide.

PMID 21613260 · Goto et al., 2011 · Open in CIViC

civic